| Management target | Revenue FY27 |
|---|
| Revenue growth | ₹182 Cr revenue; YoY comparison invalid due to Numed acquisition consolidation. |
|---|---|
| Margins | Gross margin improved to 41.8%; EBITDA impacted by elevated air-freight costs. |
| Order book | 7.5-year exclusive OTC supply agreement with Ebos/TerryWhite worth ₹1300 Cr. |
| Demand visibility | Strong Australian order flow; West Asia disruption causing temporary shipping delays. |
| Management confidence | Confident but pivoting strategy due to local regulatory constraints on manufacturing. |
Growth
Consolidated revenue hit ₹182 Cr. Growth is non-comparable YoY due to Numed pharmaceutical's first-time full-quarter consolidation.
Outlook
Revenue guidance for FY27 held at ₹750 Cr with 17% EBITDA margin target.
Risks
Regulatory changes in Hyderabad halted planned unit upgrades; sudden 120-day price revision lags squeeze margins.
Earnings Call Transcript filed with NSE, NSE: SAIPARENT. Summary written with AI assistance from the document.
Sai Parenterals Ltd: key numbers
- Share price
- ₹503.95
- Market cap
- ₹2,226 Cr
- Revenue (annual)
- ₹381.0 Cr
- Net profit (annual)
- ₹14.26 Cr
- P/E (TTM)
- 107.2×Sector 50.4×
- Promoter holding
- 51.16%+0.00% QoQ
- FII holding
- 4.03%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sai Parenterals Ltd
All →Sai Parenterals Annual General Meeting
Sai Parenterals held its 25th Annual General Meeting on September 10, 2026. Shareholders approved financial statements, director appointments, and various company resolutions.
Sai Parenterals Investor Presentation: Key Takeaways
Sai Parenterals is transitioning from a domestic-focused player to an export-driven CDMO/branded generic platform through major acquisitions and capacity expansion. Q1 FY27 presentation focuses on IPO proceeds variation and global accreditation strategy.
Sai Parenterals Q1 FY27 Results: Net Profit ₹7.9 Cr, Up 464.3% YoY
Sai Parenterals Ltd reported revenue from operations of ₹178.7 Cr (+435.0% YoY) and net profit of ₹7.9 Cr (+464.3% YoY) for Q1 FY27.
- Key figure
- Net profit ₹7.9 Cr · +464.3% YoY
Sai Parenterals Earnings Call: Key Takeaways
Sai Parenterals reports transformational FY26 following the Noumed acquisition. Focus shifts from asset building to monetization through vertical integration and expanding the CDMO export business.
Sai Parenterals Earnings Call: Key Takeaways
Sai Parenterals reports Q4 FY26 consolidated revenue of ₹198cr and EBITDA of ₹29cr, following the Noumed acquisition. Standalone FY26 PAT grew 64% YoY.
Sai Parenterals Q3 FY26 Results: Net Loss of ₹6.7 Cr
Sai Parenterals Ltd reported revenue from operations of ₹96.2 Cr and a net loss of ₹6.7 Cr for Q3 FY26.
- Key figure
- Net loss ₹6.7 Cr